Welcome to Multibagg AI
Log in to access personalized features
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Divis Laboratories Ltd (DIVISLAB) is currently trading at 6,191.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Divi's Laboratories Limited is a vertically integrated pharmaceutical manufacturer and CDMO that produces Active Pharmaceutical Ingredients, intermediates, peptide fragments and nutraceutical ingredients, selling into over 100 countries with a dominant export mix and multi-site manufacturing footprint focused on generics, custom synthesis and nutraceuticals. Financially, Q3 FY26 consolidated total income was ₹2,692 crore versus ₹2,401 crore year-ago, with profit before exceptional item and tax at ₹854 crore and reported profit after tax of ₹583 crore; nine-month revenue rose to ₹8,081 crore with constant-currency growth of 8.6% and material consumption improving from prior-year levels. Product and geography mix is notable: exports comprise roughly 89% of sales with Europe and the United States contributing approximately 73% of exports, while product mix in Q3 was ~43% generics and ~57% custom synthesis and nutraceuticals contributed ₹214 crore in the quarter and ₹706 crore in nine months. Operationally the company emphasises backward integration and compliance: Unit 3 at Kakinada is central to pre-chemistry supply, Unit 1 received a positive US FDA general cGMP inspection in the quarter, management is scaling peptide SPPS/LPPS capacity and advancing automation, mechanochemistry and electrochemistry to improve safety, yields and sustainability.
Over the past 52 weeks, Divis Laboratories Ltd has traded between a low of ₹4,941.70 and a high of ₹7,077.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Divis Laboratories Ltd has a market capitalization of approximately 1,63,362.73. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Divis Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 64.48 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,63,362.73 Cr, Divis Laboratories Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Divis Laboratories Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Divis Laboratories Ltd is 64.48. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The 'Biopharma Shakti' scheme, with a ₹10,000 crore outlay, is the most significant announcement. It aims to make India a global biopharma manufacturing hub, directly aligning with Divis Labs' capabilities in complex API and biologics production.
Earnings Call Transcript
Divi's submitted the Q3 FY2026 earnings-call transcript: consolidated income ₹2,692 crore, PBT before exceptional ₹854 crore, one‑time ₹74 crore labour‑code exceptional (PBT ₹780 crore), PAT ₹583 crore; positive US FDA inspection and operational updates.
Concall Transcript
Transcript of Q3 FY2026 earnings call: consolidated revenue ₹2,692 crore (+12.1% YoY), profit before exceptional item and tax ₹854 crore, PBT ₹780 crore after a one‑time ₹74 crore labour‑code exceptional charge; PAT ₹583 crore; positive US FDA inspection and operational updates across Generics, Custom Synthesis, Peptides and Nutraceuticals.
Newspaper Publication
Divi's Laboratories published copies of Board‑approved standalone and consolidated unaudited financial results for the quarter and nine months ended Dec 31, 2025 (approved Feb 11, 2026) in Financial Express and Andhra Prabha.
Board Meeting Outcome
Divi's Laboratories Limited announced the approval of the unaudited financial results for the quarter and nine months ended December 31, 2025, during its Board Meeting on February 11, 2026.
Bearish
1
Neutral
8
Bullish
5
Bearish
24
Neutral
8
Bullish
14
Bearish
23
Neutral
0
Bullish
9
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
6153.75 | 1,63,363 Cr | 64.48 | 10.60 | 0.49 | 16.12 | 20.29 | 13.66 | |
13236.00 | 16,989 Cr | 94.80 | 10.49 | 0.09 | 12.09 | 14.48 | 7.07 | |
2039.25 | 16,667 Cr | 58.18 | 11.79 | 0.07 | 15.84 | 21.30 | 16.80 | |
891.00 | 14,278 Cr | 30.76 | 2.17 | 0.56 | 7.25 | 7.77 | 3.18 | |
316.10 | 3,411 Cr | 72.00 | 12.90 | 0.21 | 18.26 | 19.25 | 12.68 | |
372.70 | 3,391 Cr | 16.79 | 2.31 | 0.27 | 13.56 | 13.12 | 7.75 | |
338.10 | 3,191 Cr | 35.33 | 4.37 | 0.11 | 11.57 | 12.36 | 6.82 |
Divi's Laboratories Limited is a vertically integrated pharmaceutical manufacturer and CDMO that produces Active Pharmaceutical Ingredients, intermediates, peptide fragments and nutraceutical ingredients, selling into over 100 countries with a dominant export mix and multi-site manufacturing footprint focused on generics, custom synthesis and nutraceuticals.
Financially, Q3 FY26 consolidated total income was ₹2,692 crore versus ₹2,401 crore year-ago, with profit before exceptional item and tax at ₹854 crore and reported profit after tax of ₹583 crore; nine-month revenue rose to ₹8,081 crore with constant-currency growth of 8.6% and material consumption improving from prior-year levels.
Product and geography mix is notable: exports comprise roughly 89% of sales with Europe and the United States contributing approximately 73% of exports, while product mix in Q3 was ~43% generics and ~57% custom synthesis and nutraceuticals contributed ₹214 crore in the quarter and ₹706 crore in nine months.
Operationally the company emphasises backward integration and compliance: Unit 3 at Kakinada is central to pre-chemistry supply, Unit 1 received a positive US FDA general cGMP inspection in the quarter, management is scaling peptide SPPS/LPPS capacity and advancing automation, mechanochemistry and electrochemistry to improve safety, yields and sustainability.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs
1,63,363 Cr
Low Risk
64.5
55.6
4.7
10.6
7,077.70
4,941.70
Sales CAGR
Profit CAGR
ROE
ROCE
